A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination
with other anti-cancer drugs, will result in meaningful tumour size reduction, in patients
with colon cancer that has come back or has spread, and who have a specific biomarker in
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society